While policy makers have hailed drug price transparency laws as steps toward bringing down the high cost of drugs for US patients, questions remain as to how effective these laws are at achieving their aims. Now, in a research letter published in JAMA Network Open, researchers say that these laws are largely ineffective at revealing true transaction prices for drugs.
In recent years, a number of US states have put forward legislation that aim to increase drug cost transparency, including a Nevada law that requires drug makers to report their costs to manufacture and market diabetes treatments and a Connecticut law that requires the state to list the top 10 drugs that represent substantial state spending.
While policy makers have hailed these legislative solutions as steps toward bringing down the high cost of drugs for US patients, questions remain as to how effective these laws are at achieving their aims. Now, in a research letter published in JAMA Network Open, researchers say that these laws are largely ineffective at revealing true transaction prices for drugs.
In the research letter, Martha S. Ryan and Neeraj Sood, PhD, both of the University of Southern California, analyzed state drug price transparency laws to assess whether they improve transparency across the supply chain. Ryan and Sood used the National Conference of State Legislatures’ prescription drug database to identify relevant laws that were enacted between 2015 and 2018, and evaluated whether these laws would reveal information that was previously unavailable, particularly with respect to real transaction prices, including rebates and concessions.
Among the 166 drug pricing laws that the authors identified, 35 laws in 22 states included transparency provisions, but only 7 of these laws, passed in 6 states, resulted in new disclosure of information on real transaction prices. Namely, laws in Connecticut, Louisiana, and Nevada require that pharmacy benefit managers report rebates in aggregate (but not for individual drugs). Vermont requires that net prices be reported by insurers, and Maine requires that manufactures provide net prices. Laws in Oregon and Nevada require that drug makers report their profits.
No states have passed laws that address more than 3 supply chain segments, write the authors, and no state has passed a law that reveals true transaction prices or profits across the supply chain.
“To ensure drug price legislation is useful,” the authors say, “policy makers should require that real price information, including discounts and rebates, is reported by all supply chain participants.” They add that this information would ideally be available for the products that have the biggest impact on state budgets, or that have shown large price increases.
“If requiring such disclosure at the individual-drug level would invite legal challenge, states should at least require each supply chain segment to report aggregate profits from sales in that state,” they add.
Reference
Ryan MS, Sood N. Analysis of state-level drug pricing transparency laws in the United States. JAMA Netw Open. 2019;2(9):e1912104. doi:10.1001/jamanetworkopen.2019.12104.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.